Hans Gelderblom, MD, PhD

Professor medical oncology
Leiden University Medical Center, Leiden, Netherlands, Netherlands

Prof Hans (AJ) Gelderblom is head of the department of Medical Oncology at the Leiden University Medical Center (LUMC) and chair of the Comprehensive Cancer Network West in the Netherlands. The LUMC is reference center for bone and soft tissue tumours including gastrointestinal stromal tumours.He is member of the Dutch Committee for Bone Tumours and past-chair of the EORTC Soft Tissue and Bone Sarcoma Group. He has (co) authored approximately 250 papers on (bone) sarcoma and GIST and is CTOS member since 2003.

Poster(s):

• (P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY

• (P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL

• (P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION

• (P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY

• (P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE

• (P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)

• (P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA